NCT06671977View on ClinicalTrials.gov

Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans

PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 14, 2025

Primary Completion Date

December 1, 2027

Study Completion Date

December 1, 2027

Conditions
Major Depression DisorderDepression
Interventions
DRUG

DMT-Medium Dose

14 mg slow intravenous push (bolus) over 5 minutes and then 0.015 mg/kg/min for 55 minutes.

DRUG

DMT-Low Dose

10 mg slow intravenous push (bolus) over 5 minutes and then 0.01 mg/kg/min for 55 minutes

DRUG

THC-Medium Dose

0.5 mg over 5 minutes and then 2 mg over and 55 minutes

DRUG

THC-Low Dose

0.1 mg slow intravenous push (bolus) over 5 minutes and then I mg over 55 minutes

Trial Locations (1)

06516

RECRUITING

Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine,, West Haven

All Listed Sponsors
lead

Deepak C. D'Souza

OTHER